The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease, characterized by motor neuron death in the brain and spinal cord. Mutations in the Cu/Zn superoxide dismutase (SOD1) gene account for ~20% of all familial ALS forms, corresponding to 1%–2% of all ALS cases. One of the su...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-07-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996119300774 |
| _version_ | 1818646061133070336 |
|---|---|
| author | Yulia Dzhashiashvili Chase P. Monckton Harini S. Shah Rejani B. Kunjamma Brian Popko |
| author_facet | Yulia Dzhashiashvili Chase P. Monckton Harini S. Shah Rejani B. Kunjamma Brian Popko |
| author_sort | Yulia Dzhashiashvili |
| collection | DOAJ |
| description | Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease, characterized by motor neuron death in the brain and spinal cord. Mutations in the Cu/Zn superoxide dismutase (SOD1) gene account for ~20% of all familial ALS forms, corresponding to 1%–2% of all ALS cases. One of the suggested mechanisms by which mutant SOD1 (mtSOD1) exerts its toxic effects involves intracellular accumulation of abnormal mtSOD1 aggregates, which trigger endoplasmic reticulum (ER) stress and activate its adaptive signal transduction pathways, including the unfolded protein response (UPR). PERK, an eIF2α kinase, is central to the UPR and is the most rapidly activated pathway in response to ER stress. Previous reports using mtSOD1 transgenic mice indicated that genetic or pharmacological enhancement of the UPR-PERK pathway may be effective in treating ALS. We investigated the response to PERK haploinsufficiency, and the response to deficiency of its downstream effectors GADD34 and CHOP, in five distinct lines of mtSOD1 mice. We demonstrate that, in contrast to a previously published study, PERK haploinsufficiency has no effect on disease in all mtSOD1 lines examined. We also show that deficiency of GADD34, which enhances the UPR by prolonging the phosphorylation of eIF2α, does not ameliorate disease in these mtSOD1 mouse lines. Finally, we demonstrate that genetic ablation of CHOP transcription factor, which is known to be pro-apoptotic, does not ameliorate disease in mtSOD1 mice. Cumulatively, our studies reveal that neither genetic inhibition of the UPR via ablation of PERK, nor genetic UPR enhancement via ablation of GADD34, is beneficial for mtSOD1-induced motor neuron disease. Therefore, the PERK pathway is not a likely target for therapeutic intervention in mtSOD1-induced ALS. |
| first_indexed | 2024-12-17T00:40:39Z |
| format | Article |
| id | doaj.art-c122c73995064f16913e17e3eabe376f |
| institution | Directory Open Access Journal |
| issn | 1095-953X |
| language | English |
| last_indexed | 2024-12-17T00:40:39Z |
| publishDate | 2019-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurobiology of Disease |
| spelling | doaj.art-c122c73995064f16913e17e3eabe376f2022-12-21T22:10:02ZengElsevierNeurobiology of Disease1095-953X2019-07-01127527544The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALSYulia Dzhashiashvili0Chase P. Monckton1Harini S. Shah2Rejani B. Kunjamma3Brian Popko4Department of Neurology, The University of Chicago Center for Peripheral Neuropathy, The University of Chicago, Chicago, IL 60637, United StatesDepartment of Neurology, The University of Chicago Center for Peripheral Neuropathy, The University of Chicago, Chicago, IL 60637, United StatesDepartment of Neurology, The University of Chicago Center for Peripheral Neuropathy, The University of Chicago, Chicago, IL 60637, United StatesDepartment of Neurology, The University of Chicago Center for Peripheral Neuropathy, The University of Chicago, Chicago, IL 60637, United StatesCorresponding author at: The University of Chicago, Department of Neurology, MC2030, 5841 S. Maryland Ave., Chicago, IL 60637, United States.; Department of Neurology, The University of Chicago Center for Peripheral Neuropathy, The University of Chicago, Chicago, IL 60637, United StatesAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease, characterized by motor neuron death in the brain and spinal cord. Mutations in the Cu/Zn superoxide dismutase (SOD1) gene account for ~20% of all familial ALS forms, corresponding to 1%–2% of all ALS cases. One of the suggested mechanisms by which mutant SOD1 (mtSOD1) exerts its toxic effects involves intracellular accumulation of abnormal mtSOD1 aggregates, which trigger endoplasmic reticulum (ER) stress and activate its adaptive signal transduction pathways, including the unfolded protein response (UPR). PERK, an eIF2α kinase, is central to the UPR and is the most rapidly activated pathway in response to ER stress. Previous reports using mtSOD1 transgenic mice indicated that genetic or pharmacological enhancement of the UPR-PERK pathway may be effective in treating ALS. We investigated the response to PERK haploinsufficiency, and the response to deficiency of its downstream effectors GADD34 and CHOP, in five distinct lines of mtSOD1 mice. We demonstrate that, in contrast to a previously published study, PERK haploinsufficiency has no effect on disease in all mtSOD1 lines examined. We also show that deficiency of GADD34, which enhances the UPR by prolonging the phosphorylation of eIF2α, does not ameliorate disease in these mtSOD1 mouse lines. Finally, we demonstrate that genetic ablation of CHOP transcription factor, which is known to be pro-apoptotic, does not ameliorate disease in mtSOD1 mice. Cumulatively, our studies reveal that neither genetic inhibition of the UPR via ablation of PERK, nor genetic UPR enhancement via ablation of GADD34, is beneficial for mtSOD1-induced motor neuron disease. Therefore, the PERK pathway is not a likely target for therapeutic intervention in mtSOD1-induced ALS.http://www.sciencedirect.com/science/article/pii/S0969996119300774Amyotrophic lateral sclerosisSOD1 miceMotor neuronsEndoplasmic reticulum stressUnfolded protein responsePERK |
| spellingShingle | Yulia Dzhashiashvili Chase P. Monckton Harini S. Shah Rejani B. Kunjamma Brian Popko The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS Neurobiology of Disease Amyotrophic lateral sclerosis SOD1 mice Motor neurons Endoplasmic reticulum stress Unfolded protein response PERK |
| title | The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS |
| title_full | The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS |
| title_fullStr | The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS |
| title_full_unstemmed | The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS |
| title_short | The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS |
| title_sort | upr perk pathway is not a promising therapeutic target for mutant sod1 induced als |
| topic | Amyotrophic lateral sclerosis SOD1 mice Motor neurons Endoplasmic reticulum stress Unfolded protein response PERK |
| url | http://www.sciencedirect.com/science/article/pii/S0969996119300774 |
| work_keys_str_mv | AT yuliadzhashiashvili theuprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals AT chasepmonckton theuprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals AT harinisshah theuprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals AT rejanibkunjamma theuprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals AT brianpopko theuprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals AT yuliadzhashiashvili uprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals AT chasepmonckton uprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals AT harinisshah uprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals AT rejanibkunjamma uprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals AT brianpopko uprperkpathwayisnotapromisingtherapeutictargetformutantsod1inducedals |